Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

The Use Of Intranasal (IN) Ketamine For Pain Control In Patients With Sickle Cell Disease And Vaso-occlusive Episode (VOE) In The Pediatric Emergency Department

To see complete record on, please visit this link

Id: NCT04150757

Organisation Name: New York City Health and Hospitals Corporation

Overal Status: Recruiting

Start Date: August 21, 2020

Last Update: September 1, 2021

Lead Sponsor: Abigail Nixon

Brief Summary: This will be a descriptive cohort study of intranasal ketamine as the initial analgesic for children with sickle cell disease who present to the pediatric emergency department with vaso-occlusive crisis and are awaiting intravenous line placement.

  • Sickle Cell Disease
  • Vaso-Occlusive Pain Episode in Sickle Cell Disease
  • Vaso-occlusive Crisis
  • Ketamine
  • Intranasal Ketamine
  • Analgesia

Total execution time in seconds: 0.28715801239014